Document is current

Article History

Received: 15 June 2023

Accepted: 3 January 2025

First Online: 9 January 2025

Declarations

:

: The study protocol was approved by the ethical committee at the leading study site: The Local Ethical Committee of the University Hospital in Pilsen and the Medical Faculty in Pilsen, Charles University in Prague, Czech Republic and subsequently approved by all participating sites. The study was registered in the German Clinical Trial Register – Nr. DRKS00021520. The study is being conducted across multiple sites. All patient recruitment and trial data collection is being undertaken in accordance with Good Clinical Practice (GCP). The design, analysis, interpretation of data, drafting, and revisions conform the Helsinki Declaration, the Committee on Publication Ethics (COPE) guidelines (), the STARD checklist, available through the EQUATOR (enhancing the quality and transparency of health research) network (). Only endometrial cancer patients ≥ 18 years listed for surgical treatment with sentinel lymph node mapping, with no history of other types of cancer and who provide a valid written informed consent (obtained from participants and/or their legal guardians) will be considered potentially eligible for the study.

: Not applicable- as the manuscript does not contain any identifiable information or images of study participants.

: The co-author and study coordinator of this project, Alessandra Mescalchin, is an employee of Life Science, Sysmex Europe SE, Germany, the EMEA regional headquarter of the funder, Sysmex Corporation (Kobe, Japan) that had a role in the design of the study. Therefore she has a competing interest.All other authors declare no competing interests.